Clinical Trial Update: Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma [Phase 3]

View source ↗

Summary

Phase 3 trial assessing short immunotherapy after radical surgery in patients with high-risk malignant melanoma; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Snippet

Sponsor: Uppsala University | Conditions: High-risk Melanoma | Phase 3 | Status: RECRUITING